LOGO
LOGO

Promising Endometrial Cancer Trial Data Puts Acrivon In Focus

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Endometrial cancer, a type of uterine cancer, develops when cells in the endometrium, i.e., the inner lining of the uterus, begin to grow out of control. It primarily affects post-menopausal women. The American Cancer Society estimates that about 13,250 women will die from cancers of the uterus in 2024. Treatment options for endometrial cancer vary based on its stage. If caught early, it can often be effectively managed with surgery alone or in combination with radiation or chemotherapy. However, the prognosis is considerably poorer for those whose cancer has metastasized or returned after initial treatment.

The stock we are bringing to your attention today is that of Acrivon Therapeutics Inc. (ACRV), a clinical-stage precision medicine company, which recently reported positive data from its ongoing registrational intent, phase II trial of lead drug candidate ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.